Method for improving chemotactic function of adipose-derived mesenchymal stem cells by using traditional Chinese medicine monomer components

By adding Chinese medicine monomers such as quercetin, β-sitosterol and rhubarb acid to stem cell culture medium, the chemotaxis function of fat mesenchymal stem cells is activated, and the problem of low survival rate of stem cells in the oxidative stress environment is solved, which is significantly It improves its anti-hepatic injury ability and transplant efficiency.

CN118931828APending Publication Date: 2024-11-12SHANXI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411042732.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing stem cell transplantation therapy is difficult to survive for a long time in environments such as oxidative stress, ischemia and hypoxia, resulting in low transplant efficiency, especially when treating acute liver injury, the lack of effective Chinese medicine monomer components to activate fat mesenchymal stem cells.

Method used

By adding Chinese herbal monomers such as quercetin, β-sitosterol and rhubarbic acid to high-sugar DMEM culture medium, fat mesenchymal stem cells are cultured to enhance their chemotaxis function, improve their anti-hepatic damage ability, and digest them through pancreatic enzymes and subculture technology to improve cell activity.

Benefits of technology

It significantly improves the chemokine receptor expression of fat mesenchymal stem cells, enhances its anti-hepatic injury ability, and improves the success rate of stem cell transplantation and liver protection effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931828A_ABST
    Figure CN118931828A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of mesenchymal stem cells and application thereof, in particular to a method for improving the chemotactic function of adipose-derived mesenchymal stem cells through traditional Chinese medicine monomer components. In order to improve the chemotactic function of the adipose-derived stem cells, quercetin, beta-sitosterol, rhein and a composition thereof are respectively added into the culture medium, the expression of chemotactic factor receptors of the cultured adipose-derived stem cells is increased, and the adipose-derived stem cells have relatively strong liver injury resistance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of mesenchymal stem cells and their application, and in particular to a method for improving the chemotaxis function of adipose mesenchymal stem cells using a Chinese medicine monomer component. Background Art

[0002] Acute liver injury refers to a clinical disease in which a person who has no liver disease or has liver disease but is in a stable state is directly or indirectly exposed to various liver damage hazards, resulting in a sharp deterioration of liver function within 2 weeks, combined with abnormalities in related laboratory indicators such as liver enzymes, bilirubin, and coagulation function. Acute liver failure is a serious stage of ALI. It is caused by the necrosis or damage of a large number of liver cells in a short period of time, resulting in serious disorders or decompensation of the liver's synthesis, detoxification, metabolism, and biotransformation functions, which is life-threatening in severe cases. Once acute liver failure occurs, liver transplantation will be the only effective treatment. However, the lack of liver sources, high transplantation costs, strong immune rejection reactions after transplantation, and many postoperative complications have led to a low clinical application rate of liver transplantation technology. Therefore, with the development of regenerative medicine, stem cell transplantation has become an effective alternative to liver transplantation for the treatment of acute liver failure.

[0003] However, stem cell transplantation therapy also has obvious shortcomings. Since the lesion site is often in an environment of oxidative stress, ischemia and hypoxia, it is not conducive to the long-term survival of transplanted stem cells, resulting in low stem cell transplantation efficiency.

[0004] Extensive research has been conducted to enhance the activity of transplanted stem cells and improve the efficiency of transplantation so that they can effectively exert their biological effects. However, there are few studies on the use of Chinese medicine monomer components in vitro to enhance the proliferation capacity of adipose-derived mesenchymal stem cells and exert liver protection. In particular, there have been no reports on the effects of Chinese medicine monomer components such as quercetin, β-sitosterol and rhein in Artemisia annua decoction and their compatibility on adipose-derived mesenchymal stem cells. The development of Chinese medicine monomers and compatibility to enhance the activity of adipose-derived mesenchymal stem cells and improve the success rate of stem cell transplantation is conducive to the development of new drugs for the treatment of acute liver injury with adipose-derived mesenchymal stem cells. Summary of the invention

[0005] In view of the above problems existing in the prior art, the present invention provides a method for improving the chemotactic function of adipose-derived mesenchymal stem cells by using a Chinese medicine monomer component, and using the adipose-derived mesenchymal stem cells to treat acute liver injury.

[0006] In order to achieve the above object, the present invention provides a method for improving the chemotactic function of adipose-derived mesenchymal stem cells by using a Chinese medicine monomer component, comprising the following steps:

[0007] Step 1, culturing adipose-derived mesenchymal stem cells, wherein the culture medium is: a high-glucose DMEM culture medium supplemented with a Chinese medicine monomer and fetal bovine serum, wherein the Chinese medicine monomer is one, two or three of quercetin, β-sitosterol and rhein;

[0008] Step 2: When the cell confluence is 70-80%, the cells are digested with trypsin digestion solution containing EDTA, and then centrifuged and adipose-derived mesenchymal stem cells are collected for subculture.

[0009] Furthermore, in step 1, the concentrations of quercetin, β-sitosterol and rhein in the culture medium are 10 μmol / L, 20 μmol / L and 5 μmol / L respectively.

[0010] Specifically, when the Chinese medicine monomer is quercetin, β-sitosterol or rhein, the concentrations in the culture medium are 10 μmol / L, 20 μmol / L and 5 μmol / L, respectively.

[0011] When the Chinese medicine monomers are quercetin and β-sitosterol, their concentrations in the culture medium are 10 μmol / L and 20 μmol / L, respectively.

[0012] When the Chinese medicine monomers are quercetin and rhein, their concentrations in the culture medium are 10 μmol / L and 5 μmol / L, respectively.

[0013] When the Chinese medicine monomers are β-sitosterol and rhein, their concentrations in the culture medium are 20 μmol / L and 5 μmol / L, respectively.

[0014] When the Chinese medicine monomers are quercetin, β-sitosterol and rhein, their concentrations in the culture medium are 10 μmol / L, 20 μmol / L and 5 μmol / L, respectively.

[0015] Furthermore, in step 1, the volume fraction of fetal bovine serum in the culture medium is 20%.

[0016] Furthermore, the volume fraction of the pancreatic digestion solution in step 2 is 0.25%.

[0017] Furthermore, the centrifugal speed in step 2 is 2000 r / min and the time is 3-5 min.

[0018] The present invention also provides adipose-derived mesenchymal stem cells obtained according to the above method.

[0019] The present invention also provides a use of the adipose-derived mesenchymal stem cells in the preparation of a drug for treating acute liver injury.

[0020] Compared with the prior art, the present invention has the following advantages:

[0021] (1) Quercetin, β-sitosterol and rhein are effective drug monomers that are significantly enriched in the liver after oral administration of Yinchenhao Decoction. Yinchenhao Decoction has the effects of clearing heat, promoting dampness and relieving jaundice, and is a commonly used prescription for the treatment of damp-heat jaundice.

[0022] (2) The present invention adds quercetin, β-sitosterol, rhein and a combination thereof to the culture medium, respectively, and the expression of chemokine receptors of the cultured mesenchymal stem cells is increased, and the cells have a stronger ability to resist liver damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a result diagram showing the changes in ALT and AST expression in the D-GalN-induced hepatocyte injury model in Example 2;

[0024] Figure 2 This is a result diagram showing the changes in ALT and AST expression in the rat model of liver injury established by intraperitoneal injection of N-nitrosodiethylamine in Example 2 after treatment with mesenchymal stem cells;

[0025] Figure 3 This is a graph showing the chemokine expression results of the injected adipose-derived mesenchymal stem cells in Example 2.

[0026] Note: A is 10μmol / L quercetin; B is 20μmol / L β-sitosterol; C is 5μmol / L rhein. DETAILED DESCRIPTION

[0027] The examples described below are implemented based on the technical solution of the present invention, and provide detailed implementation methods and specific operating procedures, but do not limit the protection scope of the patent of the present invention. Any technical solution obtained in the form of equivalent replacement or equivalent transformation should fall within the protection scope of the present invention.

[0028] Example 1

[0029] A method for improving the chemotactic function of adipose mesenchymal stem cells using a Chinese medicine monomer component, comprising the following steps:

[0030] Step 1: Chinese medicine monomer components intervene in the culture of adipose-derived mesenchymal stem cells:

[0031] Rat adipose-derived mesenchymal stem cells (Mei Lun Biotechnology, PWC-RA010) were cultured, and the culture medium was changed every 3-4 days. The culture medium was based on high-glucose DMEM culture medium, supplemented with 20% fetal bovine serum by volume, and one, two or three of quercetin, β-sitosterol, and rhein, specifically:

[0032] (1) 10 μmol / L quercetin;

[0033] (2) 20 μmol / L β-sitosterol;

[0034] (3) 5 μg / mL rhein;

[0035] (4) 10 μmol / L quercetin, 20 μmol / L β-sitosterol;

[0036] (5) 10 μmol / L quercetin, 5 μg / mL rhein;

[0037] (6) 20 μmol / L β-sitosterol, 5 μg / mL rhein;

[0038] (7) 10 μmol / L quercetin, 20 μmol / L β-sitosterol, and 5 μg / mL rhein.

[0039] Step 2: When the cell confluence is 70-80%, the adipose-derived mesenchymal stem cells are digested with a pancreatic digestion solution containing 0.25% EDTA by volume, and then centrifuged at 2000 r / min for 3-5 minutes to collect the cells and perform subculture.

[0040] Example 2

[0041] Application of adipose-derived mesenchymal stem cells expanded in Study Example 1 in treating liver injury

[0042] In vitro construction of a hepatocyte injury model induced by LPS-stimulated macrophage culture supernatant and D-GalN: After stimulating macrophages with 1 μg / mL LPS for 4 hours, the cell supernatant was collected and the hepatocytes were treated with the supernatant and 5 mg / mL D-GalN for 24 hours. Subsequently, normal adipose-derived mesenchymal stem cells and the 7 groups of adipose-derived mesenchymal stem cells obtained in Example 1 were co-cultured with hepatocytes to observe the changes in ALT and AST expression in the cell supernatant. The results are as follows: Figure 1 As shown, it can be seen that compared with the ALT / AST content in the supernatant of the hepatocyte injury model (Model), co-culture of normal adipose-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells intervened by quercetin, β-sitosterol, rhein and the combination with the hepatocyte injury model can significantly reduce the expression levels of ALT and AST in the cell supernatant, indicating that the adipose-derived mesenchymal stem cells prepared by the present invention have the ability to resist hepatocyte injury.

[0043] Intraperitoneal injection of N-nitrosodiethylamine was used to establish a rat model of liver injury: the model group rats were intraperitoneally injected with 200 mg / kg N-nitrosodiethylamine, and the expression levels of ALT and AST were detected 2 weeks later to confirm the establishment of the animal model of liver injury; there were 8 groups of rats in the treatment group, and the first group was given a tail vein injection of 1×10 6 Adipose-derived mesenchymal stem cells were injected. For comparison, normal adipose-derived mesenchymal stem cells and the 7 groups of adipose-derived mesenchymal stem cells obtained in Example 1 were injected immediately after the injection of N-nitrosodiethylamine in groups 2 to 8. The expression changes of ALT and AST were detected by an automatic biochemical analyzer. The results are as follows: Figure 2As shown, it can be seen that compared with the rats with liver damage constructed by intraperitoneal injection of N-nitrosodiethylamine (Model group), the expression levels of ALT and AST in the serum of rats in each group decreased after tail vein injection of adipose-derived mesenchymal stem cells, indicating that the adipose-derived mesenchymal stem cells activated and expanded by combined traditional Chinese medicine prepared by the present invention still have the ability to resist liver damage in vivo.

[0044] Example 3

[0045] The mechanism of the adipose-derived mesenchymal stem cells expanded in Example 1 in treating liver injury was studied.

[0046] Normal adipose-derived mesenchymal stem cells in Study Example 1 and groups 1 to 7 of adipose-derived mesenchymal stem cells were collected, and total cell RNA was extracted using RNAiso Plus (TaKaRa) reagent. The RNA quality and concentration were detected by spectrophotometry. The RNA was reverse transcribed into cDNA using the 5× PrimeScript RT MasterMix kit. The SYBR Green method was used to perform reverse transcription of cDNA (100 ng) as a template in QuantStudio 5, instrument detection, and the reaction system and conditions were referred to TB. PremixEx Taq TM (Tli RNaseH Plus) (Ta KaRa) instructions. After the reaction is completed, use 2 -ΔΔCt Relative quantitative analysis of gene expression was performed.

[0047] The upstream primer of the internal reference GAPDH was 5′-CATCTCCCTCACAATTCCATCC-3′, and the downstream primer was 5′-GAGGGTGCAGCGAACTTTAT-3′;

[0048] The upstream primer for the target gene CCR1 was 5′-AGGCCCAGAAACAAAGTCTG-3′, and the downstream primer was 5′-AGCAGTCTTTTGGCATGGAGT-3′;

[0049] The upstream primer of the target gene CXCR4 was 5'-GGCTGACCTCTTTGT-3', and the downstream primer was 5'-AGCAGTCTTTTGGCATGGAGT-3'.

[0050] Test results such as Figure 3 As shown, it can be seen that compared with the mesenchymal stem cells not treated with traditional Chinese medicine (Control), the mesenchymal stem cells treated with traditional Chinese medicine (quercetin, β-sitosterol, rhein) expressed more CCR1 and CXCR4, indicating that the mesenchymal stem cells activated and expanded by combined traditional Chinese medicine prepared by the present invention have strong chemotactic ability.

Claims

1. A method for improving the chemotactic function of adipose-derived mesenchymal stem cells using a Chinese medicine monomer component, characterized in that: The steps include: Step 1, culturing adipose-derived mesenchymal stem cells, wherein the culture medium is: a high-glucose DMEM culture medium supplemented with a Chinese medicine monomer and fetal bovine serum, wherein the Chinese medicine monomer is one, two or three of quercetin, β-sitosterol and rhein; Step 2: When the cell confluence is 70-80%, the cells are digested with trypsin digestion solution containing EDTA, and then centrifuged and adipose-derived mesenchymal stem cells are collected for subculture.

2. The method for improving the chemotactic function of adipose-derived mesenchymal stem cells using a Chinese medicine monomer component according to claim 1, characterized in that: In step 1, the concentrations of quercetin, β-sitosterol and rhein in the culture medium are 10 μmol / L, 20 μmol / L and 5 μmol / L respectively.

3. The method for improving the chemotactic function of adipose-derived mesenchymal stem cells using a Chinese medicine monomer component according to claim 1 or 2, characterized in that: In step 1, the volume fraction of fetal bovine serum in the culture medium is 20%.

4. The method for improving the chemotactic function of adipose-derived mesenchymal stem cells using a Chinese medicine monomer component according to claim 1, characterized in that: The volume fraction of the pancreatic digestion solution in step 2 is 0.25%.

5. The method for improving the chemotactic function of adipose-derived mesenchymal stem cells using a Chinese medicine monomer component according to claim 1, characterized in that: The centrifugal speed in step 2 is 2000 r / min and the time is 3-5 min.

6. Adipose-derived mesenchymal stem cells obtained according to any one of claims 1 to 5.

7. Use of the adipose-derived mesenchymal stem cells according to claim 6 in the preparation of a drug for treating acute liver injury.